3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms, Unknown Primary
1
Gastrointestinal Neoplasms
1
Interventions
Oxaliplatin
3
Irinotecan
3
Surveys and Questionnaires
2
Specimen Handling
2
Radiosurgery
2
Leucovorin
2
Ketamine
2
Hydroxychloroquine
2
Fluorouracil
2
Capecitabine
2
ulixertinib
1
tegafur-gimeracil-oteracil
1
regorafenib
1
pazopanib
1
lanreotide
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
dolasetron
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
danvatirsen
1
cobimetinib
1
brivanib
1
auricularum
1
atezolizumab
1
alectinib
1
aldesleukin
1
abelacimab
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gastrointestinal Neoplasms
×
Mebendazole
×
Clear all
NCT03628079
2020-01-22
RepoMeb
Repos Pharma
Phase 1/2
Terminated
11 enrolled